CLINICAL TRIALS PROFILE FOR BCG VACCINE

All Clinical Trials for bcg vaccine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000105 ↗	Vaccination With Tetanus and KLH to Assess Immune Responses.	Terminated	Masonic Cancer Center, University of Minnesota		2002-07-01	The purpose of this study is to learn how the immune system works in response to vaccines. We will give the vaccines to subjects who have cancer but have not had treatment, and to patients who have had chemotherapy or stem cell transplant. Some patients will get vaccines while they are on treatments which boost the immune system (like the immune stimulating drug interleukin-2 or IL-2). Although we have safely treated many patients with immune boosting drugs, we do not yet know if they improve the body's immune system to respond better to a vaccine. Some healthy volunteers will also be given the vaccines in order to serve as control subjects to get a good measure of the normal immune response. We will compare the patients and the healthy volunteers to study how their immune systems respond to the vaccines. There are several different types of white cells in the blood. We are interested in immune cells in the blood called T-cells. These T-cells detect foreign substances in the body (like viruses and cancer cells). We are trying to learn more about how the body fights these foreign substances. Our goal is to develop cancer vaccines which would teach T-cells to detect and kill cancer cells better. We know that in healthy people the immune system effectively protects against recurrent virus infection. For example, that is why people only get "mono" (mononucleosis) once under normal circumstances. When the body is infected with the "mono" virus, the immune system remembers and prevents further infection. We are trying to use the immune system to prevent cancer relapse. To test this, we will give two vaccines which have been used to measure these immune responses. Blood samples will be studied from cancer patients and will be compared to similar samples from normal subjects.
NCT00000755 ↗	A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3	Completed	Genentech, Inc.	Phase 1	1969-12-31	To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens.
NCT00000755 ↗	A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3	Completed	Glaxo Wellcome	Phase 1	1969-12-31	To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens.
NCT00000755 ↗	A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens.
NCT00000820 ↗	A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	PRIMARY: To examine the effect of aldesleukin ( IL-2 ) on viral activity in the blood. To determine the safety of low-dose IL-2 in combination with antiretroviral therapy versus antiretroviral therapy alone. SECONDARY: To examine delayed type hypersensitivity responses to skin test antigens and antibody responses to protein and polysaccharide vaccines. The profound immune impairment that results from HIV-1 infection is due, at least in part, to the loss of CD4+ T cells and the cytokines these cells secrete, especially IL-2 and interferon-gamma. Antiretroviral agents do not directly address the problem of immune impairment. Replacement of IL-2 at nontoxic doses may prevent or delay clinical immunosuppression and its attendant opportunistic infections. Also, since patients with HIV-1 infection respond suboptimally to routine protein and polysaccharide immunizations, IL-2 may provide an adjuvant effect on vaccine responses.

Clinical Trial Conditions for bcg vaccine

Condition Name

Condition Name for bcg vaccine
Intervention	Trials
Influenza	71
COVID-19	59
HIV Infections	45
Melanoma	42

Condition MeSH

Condition MeSH for bcg vaccine
Intervention	Trials
COVID-19	140
Influenza, Human	122
Melanoma	104
HIV Infections	71

Clinical Trial Locations for bcg vaccine

Trials by Country

Trials by Country for bcg vaccine
Location	Trials
France	90
Italy	75
Belgium	64
South Africa	60
Brazil	54

Trials by US State

Trials by US State for bcg vaccine
Location	Trials
Maryland	279
California	210
New York	201
Texas	193
Florida	156

Clinical Trial Progress for bcg vaccine

Clinical Trial Phase

Clinical Trial Phase for bcg vaccine
Clinical Trial Phase	Trials
PHASE4	20
PHASE3	8
PHASE2	36

Clinical Trial Status

Clinical Trial Status for bcg vaccine
Clinical Trial Phase	Trials
Completed	738
Recruiting	360
Not yet recruiting	193

Clinical Trial Sponsors for bcg vaccine

Sponsor Name

Sponsor Name for bcg vaccine
Sponsor	Trials
National Cancer Institute (NCI)	211
National Institute of Allergy and Infectious Diseases (NIAID)	185
GlaxoSmithKline	74

Sponsor Type

Sponsor Type for bcg vaccine
Sponsor	Trials
Other	1896
Industry	888
NIH	449

Bcg vaccine Market Analysis and Financial Projection

Last updated: April 25, 2026

Clinical Trials Update, Market Analysis, and Projection for BCG Vaccine

What is BCG vaccine’s clinical and regulatory status globally?

BCG (Bacillus Calmette-Guérin) is an established live attenuated vaccine for prevention of tuberculosis (TB). It is marketed in multiple jurisdictions as an immunization product and, in many settings, is used as part of national TB control programs. Most jurisdictions treat BCG as an established product category with long-standing registrations and manufacturing oversight under local product licensing frameworks.

Evidence base and clinical trial posture

• BCG remains the backbone of TB vaccination programs in high TB burden countries.
• Clinical development activity is focused on:
  • New strain candidates and improved manufacturing/consistency.
  • BCG re-vaccination strategies.
  • Combination approaches (BCG plus adjunct immunotherapies).
  • Post-exposure and oncology-adjunct research, where BCG is already therapeutically used as an intravesical treatment in bladder cancer in some regions (clinical development focus varies by geography).

Because BCG is not a single “modern blockbuster” pipeline asset with one standardized phase-3 program, trial updates must be interpreted as a portfolio of studies rather than one late-stage readout. Clinical activity still appears in:

• TB prevention substudies (efficacy, immunogenicity, duration of response, booster strategies).
• Comparative strain and regimen trials.
• Combination immunotherapy explorations.

Key operational takeaway

• Investment and R&D signals for BCG are driven less by “new molecular entity timelines” and more by supply security, manufacturing competitiveness, and program-level tendering in TB-endemic markets.

---

What is the current clinical trials landscape for BCG vaccine?

BCG clinical trial activity typically concentrates in three themes:

1) TB protection and durability studies

• Trials evaluate baseline protection, immunogenicity durability, and the effect of revaccination schedules.
• Many studies compare BCG regimens across age groups, dosing schedules, and strain types.

2) BCG strain and manufacturing comparability

• Clinical and immunogenicity studies assess whether strain selection and manufacturing changes alter immune readouts.
• These trials feed regulatory comparability packages and help stabilize global supply.

3) BCG as an immunotherapy platform

• Research expands beyond TB into:
  • Non-TB infectious disease prevention hypotheses.
  • Oncology adjunct concepts building on the broader clinical experience of BCG immunotherapy (notably intravesical use for bladder cancer, which is an established clinical practice rather than a vaccine-alone program in most markets).

Implication for trial update readers

• “Update” in BCG is best read as ongoing immunology and program optimization rather than a single definitive Phase 3 efficacy pivot.

---

What do market dynamics say about demand for BCG vaccine?

BCG demand is shaped by TB incidence, infant birth cohorts, national vaccination program coverage, and procurement cycles.

1) Demand drivers

• Large eligible birth cohorts in TB high burden regions.
• Persistent TB incidence keeps infant vaccination programs active.
• Programmatic procurement: tenders and multi-year supply contracts are common in endemic markets.

2) Supply drivers

• BCG is produced by a limited number of manufacturers and relies on controlled live organism manufacturing.
• Supply continuity is critical because of:
  • Manufacturing complexity for live attenuated products.
  • Stability and logistics constraints.
  • Regulatory batch-release demands.

3) Pricing and procurement structure

• BCG is generally a low to mid-price vaccine compared with newer premium biologics, but volumes are high.
• Market value is driven by:
  • Coverage and health system spending.
  • Tender-based pricing.
  • Product availability and allocation during supply constraints.

---

How big is the BCG vaccine market and what is the near-term trajectory?

A rigorous quant projection requires a single consistent source series (e.g., global market forecasts with year-by-year values). In the absence of a specific, citable forecast dataset in this task, the most decision-relevant projection logic is to model market growth by:

• TB epidemiology: steady or slowly changing incidence trends.
• Birth cohort growth in high-burden regions.
• Coverage expansion vs. plateau: improvements in immunization coverage can drive incremental growth.
• Supply improvements: when supply stabilizes, procurement can track coverage targets more closely.

Actionable projection framework (useful for business planning)

• Base-case growth is typically modest in mature markets and more variable in endemic markets due to procurement cycles.
• Upside cases come from:
  • Coverage improvements.
  • Larger-than-planned tender volumes.
  • Replacement of constrained suppliers or expanded inclusion in national schedules.
• Downside cases come from:
  • Funding volatility for immunization programs.
  • Supply disruptions and allocation constraints.
  • Substitution with alternative strategies where national policy shifts away from routine BCG.

---

Where is growth most likely: by region and procurement behavior?

BCG demand is structurally concentrated in high TB burden geographies. The most relevant market lens is not “where incidence exists” alone, but where routine immunization procurement and delivery infrastructure can reliably purchase and distribute BCG.

High-likelihood demand regions

• Regions with persistent high TB burden and ongoing infant immunization programs.
• Countries where donor-backed procurement schedules exist or where national immunization budget allocations are stable.

Procurement behavior

• Tenders often favor proven supply track record and batch release reliability.
• Supplier switching is limited by:
  • Regulatory and pharmacovigilance transitions.
  • Cold-chain and logistics competence.
  • Demonstrated potency and consistency.

---

What is the competitive landscape for BCG vaccine supply?

BCG competition in practice is defined by:

• Ability to meet tender volumes reliably.
• Batch consistency (potency and release controls).
• Regulatory compliance and established distribution networks.
• Country-level approvals and national immunization program relationships.

Competitive implications

• New entrants face barriers from:
  • Live organism manufacturing and characterization.
  • Time required to achieve country-level registrations and tender credibility.
• Incumbents with established supply can defend share through allocation reliability more than through price wars.

---

What are the key R&D and IP considerations for BCG vaccine?

BCG is a legacy vaccine with long scientific history. For patent analytics, the typical pattern for BCG is:

• Core vaccine biology and early foundational rights have largely aged.
• The actionable IP value in modern markets is more often found in:
  • Process improvements and manufacturing method claims.
  • Formulation, stabilization, and handling controls for distribution.
  • Analytical comparability methods supporting batch release and biosimilar-like pathways.
  • Clinical use claims for specific regimens (where enforceable in jurisdictions that allow method-of-use claims).

Because BCG is widely used and many claims may have expired or narrowed, commercial advantage in many countries comes more from manufacturing excellence and regulatory execution than from enforceable brand-like exclusivity.

---

What investment and commercial decisions follow from this update?

For R&D strategy

• Prioritize work that strengthens:
  • Manufacturing comparability and consistency.
  • Immunogenicity readouts supporting policy adoption.
  • Combination or regimen studies only where they can move policy or tender inclusion.

For market entry and scaling

• Treat registration and batch-release readiness as the critical path.
• Plan for tender cycles and procurement tender eligibility requirements.

For portfolio and partnership

• The most realistic “growth” levers are supply reliability and program inclusion rather than expecting breakthrough efficacy claims in a classic Phase 3 sense.

---

Key Takeaways

• BCG is an established global TB vaccine with clinical activity focused on regimen optimization, strain comparability, and combination platform research rather than a single dominant late-stage pivot.
• Market demand is driven by TB epidemiology and routine infant immunization procurement, with sales value concentrated in high-burden regions and tender-based allocation.
• Growth is more likely to be modest and procurement-linked, with upside from stable supply and expanded coverage and downside from funding or supply disruptions.
• Competitive advantage often reflects manufacturing reliability and regulatory execution more than enforceable IP exclusivity.

---

FAQs

1) Is BCG still actively studied in clinical trials?
Yes. Ongoing studies focus on regimen strategy, immunogenicity durability, strain comparability, and combination concepts, reflecting policy and program optimization rather than one single definitive efficacy program.

2) What drives BCG vaccine market demand?
Routine TB immunization schedules, infant birth cohorts, and procurement decisions tied to national immunization program budgets and tenders in high TB burden regions.

3) What is the main risk for suppliers in BCG?
Supply continuity and batch release reliability for a live attenuated product, which directly affects tender allocation and country-level trust.

4) Does BCG have strong patent life remaining?
Commercially enforceable exclusivity is often limited compared with newer biologics; competitive advantage typically depends more on manufacturing and regulatory execution than on broad, long-term exclusivity.

5) Where do growth opportunities typically arise?
Increases in immunization coverage, replacement of supply-constrained sources, and program-level inclusion where reliable supply and regulatory readiness unlock additional procurement volume.

---

References

[1] World Health Organization (WHO). Global tuberculosis report (latest available editions). World Health Organization.
[2] WHO. BCG vaccine position/technical guidance documents (latest available). World Health Organization.
[3] WHO. Immunization and vaccine-related coverage and program documentation (latest available). World Health Organization.
[4] ClinicalTrials.gov. BCG vaccine and Bacillus Calmette-Guérin interventional study listings (ongoing and completed). National Library of Medicine.